Janux Historical Balance Sheet

JANX Stock

USD 48.82 1.49 2.96%

Trend analysis of Janux Therapeutics balance sheet accounts such as Other Current Liabilities of 4.6 M or Total Current Liabilities of 11 M provides information on Janux Therapeutics' total assets, liabilities, and equity, which is the actual value of Janux Therapeutics to its prevalent stockholders. By breaking down trends over time using Janux Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Janux Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Janux Therapeutics is a good buy for the upcoming year.

Janux Therapeutics Inventory

(2.09 Million)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Janux Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

About Janux Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Janux Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Janux Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Janux Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Janux currently owns. An asset can also be divided into two categories, current and non-current.

Janux Therapeutics Balance Sheet Chart

At this time, Janux Therapeutics' Property Plant Equipment is fairly stable compared to the past year. Other Liabilities is likely to rise to about 2.4 M in 2024, whereas Total Assets are likely to drop slightly above 251.1 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Capital Stock

Add Fundamental

Total Assets

Total assets refers to the total amount of Janux Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Janux Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Janux Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Janux Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Most accounts from Janux Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Janux Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Janux Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.At this time, Janux Therapeutics' Property Plant Equipment is fairly stable compared to the past year. Other Liabilities is likely to rise to about 2.4 M in 2024, whereas Total Assets are likely to drop slightly above 251.1 M in 2024.

	2022	2023	2024 (projected)
Short and Long Term Debt Total	25.3M	24.5M	14.9M
Total Assets	364.0M	380.4M	251.1M

Short Long Term Debt Total Total Assets

Janux Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt
Total Assets		0.71	0.97	0.97	1.0	0.97	0.79	-0.63	-0.84	1.0	0.91	0.8	0.75	1.0	0.96	0.43	0.52	0.99	0.74	1.0	0.79	-0.48	1.0	1.0	1.0	-0.81
Short Long Term Debt Total	0.71		0.84	0.79	0.69	0.7	0.94	-0.11	-0.86	0.68	0.65	0.93	0.81	0.68	0.74	0.53	0.68	0.75	0.8	0.69	0.93	-0.53	0.68	0.74	0.68	-0.39
Other Current Liab	0.97	0.84		0.97	0.96	0.94	0.89	-0.53	-0.9	0.97	0.9	0.89	0.8	0.96	0.95	0.48	0.65	0.99	0.84	0.96	0.88	-0.51	0.96	0.98	0.96	-0.76
Total Current Liabilities	0.97	0.79	0.97		0.97	0.94	0.84	-0.62	-0.83	0.96	0.95	0.84	0.72	0.97	0.94	0.39	0.52	0.96	0.75	0.97	0.83	-0.44	0.97	0.97	0.96	-0.71
Total Stockholder Equity	1.0	0.69	0.96	0.97		0.97	0.77	-0.64	-0.83	1.0	0.9	0.78	0.73	1.0	0.96	0.42	0.48	0.99	0.7	1.0	0.77	-0.47	1.0	1.0	1.0	-0.79
Net Tangible Assets	0.97	0.7	0.94	0.94	0.97		0.84	-0.52	-0.9	0.97	0.87	0.85	0.84	0.97	1.0	0.61	0.5	0.97	0.72	0.97	0.84	-0.66	0.97	0.97	0.97	-0.8
Property Plant And Equipment Net	0.79	0.94	0.89	0.84	0.77	0.84		-0.18	-0.96	0.78	0.75	1.0	0.92	0.77	0.88	0.72	0.73	0.83	0.86	0.77	1.0	-0.74	0.77	0.81	0.77	-0.59
Net Debt	-0.63	-0.11	-0.53	-0.62	-0.64	-0.52	-0.18		0.16	-0.62	-0.78	-0.18	0.01	-0.65	-0.47	0.29	-0.22	-0.57	-0.38	-0.63	-0.15	-0.22	-0.65	-0.59	-0.65	0.66
Retained Earnings	-0.84	-0.86	-0.9	-0.83	-0.83	-0.9	-0.96	0.16		-0.84	-0.71	-0.97	-0.98	-0.82	-0.93	-0.8	-0.68	-0.88	-0.81	-0.83	-0.97	0.82	-0.83	-0.86	-0.83	0.67
Accounts Payable	1.0	0.68	0.97	0.96	1.0	0.97	0.78	-0.62	-0.84		0.9	0.79	0.75	1.0	0.96	0.45	0.52	0.99	0.73	1.0	0.78	-0.5	1.0	1.0	1.0	-0.82
Cash	0.91	0.65	0.9	0.95	0.9	0.87	0.75	-0.78	-0.71	0.9		0.75	0.57	0.91	0.87	0.27	0.57	0.89	0.77	0.9	0.72	-0.32	0.91	0.9	0.91	-0.79
Non Current Assets Total	0.8	0.93	0.89	0.84	0.78	0.85	1.0	-0.18	-0.97	0.79	0.75		0.93	0.78	0.89	0.73	0.73	0.84	0.86	0.78	1.0	-0.75	0.78	0.82	0.78	-0.6
Non Currrent Assets Other	0.75	0.81	0.8	0.72	0.73	0.84	0.92	0.01	-0.98	0.75	0.57	0.93		0.73	0.87	0.9	0.6	0.79	0.71	0.73	0.94	-0.9	0.73	0.77	0.73	-0.57
Cash And Short Term Investments	1.0	0.68	0.96	0.97	1.0	0.97	0.77	-0.65	-0.82	1.0	0.91	0.78	0.73		0.96	0.42	0.49	0.99	0.71	1.0	0.76	-0.47	1.0	1.0	1.0	-0.81
Common Stock Total Equity	0.96	0.74	0.95	0.94	0.96	1.0	0.88	-0.47	-0.93	0.96	0.87	0.89	0.87	0.96		0.65	0.55	0.97	0.75	0.96	0.88	-0.69	0.96	0.97	0.96	-0.79
Common Stock Shares Outstanding	0.43	0.53	0.48	0.39	0.42	0.61	0.72	0.29	-0.8	0.45	0.27	0.73	0.9	0.42	0.65		0.43	0.48	0.47	0.42	0.76	-1.0	0.42	0.45	0.42	-0.39
Non Current Liabilities Total	0.52	0.68	0.65	0.52	0.48	0.5	0.73	-0.22	-0.68	0.52	0.57	0.73	0.6	0.49	0.55	0.43		0.58	0.96	0.47	0.73	-0.43	0.5	0.53	0.5	-0.69
Other Stockholder Equity	0.99	0.75	0.99	0.96	0.99	0.97	0.83	-0.57	-0.88	0.99	0.89	0.84	0.79	0.99	0.97	0.48	0.58		0.78	0.99	0.82	-0.52	0.99	1.0	0.99	-0.81
Total Liab	0.74	0.8	0.84	0.75	0.7	0.72	0.86	-0.38	-0.81	0.73	0.77	0.86	0.71	0.71	0.75	0.47	0.96	0.78		0.7	0.85	-0.48	0.72	0.75	0.72	-0.78
Net Invested Capital	1.0	0.69	0.96	0.97	1.0	0.97	0.77	-0.63	-0.83	1.0	0.9	0.78	0.73	1.0	0.96	0.42	0.47	0.99	0.7		0.76	-0.47	1.0	1.0	1.0	-0.79
Property Plant And Equipment Gross	0.79	0.93	0.88	0.83	0.77	0.84	1.0	-0.15	-0.97	0.78	0.72	1.0	0.94	0.76	0.88	0.76	0.73	0.82	0.85	0.76		-0.77	0.77	0.81	0.76	-0.59
Short Long Term Debt	-0.48	-0.53	-0.51	-0.44	-0.47	-0.66	-0.74	-0.22	0.82	-0.5	-0.32	-0.75	-0.9	-0.47	-0.69	-1.0	-0.43	-0.52	-0.48	-0.47	-0.77		-0.47	-0.5	-0.48	0.44
Total Current Assets	1.0	0.68	0.96	0.97	1.0	0.97	0.77	-0.65	-0.83	1.0	0.91	0.78	0.73	1.0	0.96	0.42	0.5	0.99	0.72	1.0	0.77	-0.47		1.0	1.0	-0.81
Capital Stock	1.0	0.74	0.98	0.97	1.0	0.97	0.81	-0.59	-0.86	1.0	0.9	0.82	0.77	1.0	0.97	0.45	0.53	1.0	0.75	1.0	0.81	-0.5	1.0		1.0	-0.78
Net Working Capital	1.0	0.68	0.96	0.96	1.0	0.97	0.77	-0.65	-0.83	1.0	0.91	0.78	0.73	1.0	0.96	0.42	0.5	0.99	0.72	1.0	0.76	-0.48	1.0	1.0		-0.82
Short Term Debt	-0.81	-0.39	-0.76	-0.71	-0.79	-0.8	-0.59	0.66	0.67	-0.82	-0.79	-0.6	-0.57	-0.81	-0.79	-0.39	-0.69	-0.81	-0.78	-0.79	-0.59	0.44	-0.81	-0.78	-0.82

Click cells to compare fundamentals

Janux Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Janux Historical Balance Sheet

Janux Therapeutics Inventory

(2.09 Million)

About Janux Balance Sheet Analysis

Janux Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Capital Stock

Janux Therapeutics balance sheet Correlations

Janux Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Janux Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Capital Stock	+ 1.0	Total Assets

Short Long Term Debt	- 1.0	Common Stock Shares Outstanding
Non Currrent Assets Other	- 0.98	Retained Earnings
Property Plant And Equipment Gross	- 0.97	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net
Common Stock Total Equity	- 0.93	Retained Earnings